Calcium-channel blockers: Clinical outcome associations with reported pharmacogenetics variants in 32 000 patients.

ABSTRACT:

Aims

Pharmacogenetic variants impact dihydropyridine calcium-channel blockers (dCCBs; e.g., amlodipine) treatment efficacy, yet evidence on clinical outcomes in routine primary care is limited. Reported associations in pharmacogenomics knowledge base PharmGKB have weak supporting evidence. We aimed to estimate associations between reported pharmacogenetic variants and incident adverse events in a community-based cohort prescribed dCCB.

Methods

We analysed up to 32 360 UK Biobank participants prescribed dCCB in primary care (from UK general practices, 1990-2017). We investigated 23 genetic variants. Outcomes were incident diagnosis of coronary heart disease, heart failure (HF), chronic kidney disease, oedema and switching antihypertensive medication.

Results

Participan

SUBMITTER: Turkmen D 

PROVIDER: S-EPMC10091789 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature